Table of Contents Author Guidelines Submit a Manuscript
The Scientific World Journal
Volume 2014, Article ID 450390, 9 pages
http://dx.doi.org/10.1155/2014/450390
Research Article

Synergistic Antitumor Effect of Doxorubicin and Tacrolimus (FK506) on Hepatocellular Carcinoma Cell Lines

1Istituto Nazionale per lo Studio E la Cura dei Tumori “Fondazione Giovanni Pascale”, IRCCS, 80131 Naples, Italy
2Biochemistry, Biophysics and General Pathology Department, Second University of Naples, 80138 Naples, Italy
3Department of Onco-Hematology, S.G. Moscati Hospital, 83100 Avellino, Italy

Received 5 November 2013; Accepted 24 December 2013; Published 20 February 2014

Academic Editors: C.-H. Chen and D. Morris

Copyright © 2014 Francesca Capone et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. L.-L. Fan, G.-P. Sun, W. Wei et al., “Melatonin and Doxorubicin synergistically induce cell apoptosis in human hepatoma cell lines,” World Journal of Gastroenterology, vol. 16, no. 12, pp. 1473–1481, 2010. View at Publisher · View at Google Scholar · View at Scopus
  2. S. Costantini, F. Capone, E. Guerriero et al., “Cytokinome profile of patients with type 2 diabetes/or chronic hepatitis C infection,” PLoS One, vol. 7, Article ID e39486, 2012. View at Google Scholar
  3. H. B. El-Serag and K. L. Rudolph, “Hepatocellular carcinoma: epidemiology and molecular carcinogenesis,” Gastroenterology, vol. 132, no. 7, pp. 2557–2576, 2007. View at Publisher · View at Google Scholar · View at Scopus
  4. S.-L. Ye, T. Takayama, J. Geschwind, J. A. Marrero, and J.-P. Bronowicki, “Current approaches to the treatment of early hepatocellular carcinoma,” The Oncologist, vol. 15, pp. 34–41, 2010. View at Google Scholar · View at Scopus
  5. M. Heuer, T. Benkö, V. R. Cicinnati et al., “Effect of low-dose rapamycin on tumor growth in two human hepatocellular cancer cell lines,” Transplantation Proceedings, vol. 41, no. 1, pp. 359–365, 2009. View at Publisher · View at Google Scholar · View at Scopus
  6. M. Cervello, D. Bachvarov, N. Lampiasi et al., “Molecular mechanisms of sorafenib action in liver cancer cells,” Cell Cycle, vol. 11, pp. 2843–2855, 2012. View at Google Scholar
  7. W. Yeo, T. S. Mok, B. Zee et al., “A randomized phase III study of doxorubicin versus cisplatin/interferon α-2b/doxorubicin/fluorouracil (PIAF) combination chemotherapy for unresectable hepatocellular carcinoma,” Journal of the National Cancer Institute, vol. 97, no. 20, pp. 1532–1538, 2005. View at Publisher · View at Google Scholar · View at Scopus
  8. I. Manov, Y. Pollak, R. Broneshter, and T. C. Iancu, “Inhibition of doxorubicin-induced autophagy in hepatocellular carcinoma Hep3B cells by sorafenib—The role of extracellular signal-regulated kinase counteraction,” FEBS Journal, vol. 278, no. 18, pp. 3494–3507, 2011. View at Publisher · View at Google Scholar · View at Scopus
  9. A. Mantovani, P. Romero, A. K. Palucka, and F. M. Marincola, “Tumour immunity: effector response to tumour and role of the microenvironment,” The Lancet, vol. 371, no. 9614, pp. 771–783, 2008. View at Publisher · View at Google Scholar · View at Scopus
  10. S. Costantini, F. Capone, E. Guerriero, and G. Castello, “An approach for understanding the inflammation and cancer relationship,” Immunology Letters, vol. 126, no. 1-2, pp. 91–92, 2009. View at Publisher · View at Google Scholar · View at Scopus
  11. X.-W. Cao, Z.-R. Fu, and G.-S. Ding, “Effects of tacrolimus on proliferation, apoptosis, and fluorouracil sensitivity of liver cancer cell line of SMMC-7721,” Hepatobiliary and Pancreatic Diseases International, vol. 4, no. 2, pp. 269–273, 2005. View at Google Scholar · View at Scopus
  12. S. J. N. Choi, H. S. You, and S. Y. Chung, “Tacrolimus-induced apoptotic signal transduction pathway,” Transplantation Proceedings, vol. 40, no. 8, pp. 2734–2736, 2008. View at Publisher · View at Google Scholar · View at Scopus
  13. H. Nishikawa and Y. Osaki, “Non-B, non-C hepatocellular carcinoma,” International Journal of Oncology, vol. 43, pp. 1333–1342, 2013. View at Google Scholar
  14. F. Rusolo, B. Pucci Colonna G et al., “Evaluation of selenite effects on selenoproteins and cytokinome in human hepatoma cell lines,” Molecules, vol. 1, pp. 2549–2562, 2013. View at Google Scholar
  15. S. Costantini, G. di Bernardo, M. Cammarota et al., “Gene expression signature of human HepG2 cell line,” Gene, vol. 518, pp. 335–345, 2013. View at Google Scholar
  16. E. Guerriero, A. Sorice, F. Capone et al., “Effects of lipoic acid, caffeic acid and a synthesized lipoyl-caffeic conjugate on human hepatoma cell lines,” Molecules, vol. 16, no. 8, pp. 6365–6377, 2011. View at Publisher · View at Google Scholar · View at Scopus
  17. T.-C. Chou, “Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies,” Pharmacological Reviews, vol. 58, no. 3, pp. 621–681, 2006. View at Publisher · View at Google Scholar · View at Scopus
  18. F. Capone, S. Costantini, E. Guerriero et al., “Serum cytokine levels in patients with hepatocellular carcinoma,” European Cytokine Network, vol. 21, no. 2, pp. 99–104, 2010. View at Publisher · View at Google Scholar · View at Scopus
  19. S. Costantini, F. Capone, E. Guerriero, P. Maio, G. Colonna, and G. Castello, “Serum cytokine levels as putative prognostic markers in the progression of chronic HCV hepatitis to cirrhosis,” European Cytokine Network, vol. 21, no. 4, pp. 251–256, 2010. View at Publisher · View at Google Scholar · View at Scopus
  20. Y.-H. Shi, Z.-B. Ding, J. Zhou, S.-J. Qiu, and J. Fan, “Prognostic significance of Beclin 1-dependent apoptotic activity in hepatocellular carcinoma,” Autophagy, vol. 5, no. 3, pp. 380–382, 2009. View at Publisher · View at Google Scholar · View at Scopus
  21. K. Degenhardt, R. Mathew, B. Beaudoin et al., “Autophagy promotes tumor cell survival and restricts necrosis, inflammation, and tumorigenesis,” Cancer Cell, vol. 10, no. 1, pp. 51–64, 2006. View at Publisher · View at Google Scholar · View at Scopus
  22. J. A. Muñoz-Gámez, J. M. Rodríguez-Vargas, R. Quiles-Pérez et al., “PARP-1 is involved in autophagy induced by DNA damage,” Autophagy, vol. 5, no. 1, pp. 61–74, 2009. View at Google Scholar · View at Scopus
  23. A.-C. Piguet, D. Semela, A. Keogh et al., “Inhibition of mTOR in combination with doxorubicin in an experimental model of hepatocellular carcinoma,” Journal of Hepatology, vol. 49, no. 1, pp. 78–87, 2008. View at Publisher · View at Google Scholar · View at Scopus
  24. D. C. Rubinsztein, P. Codogno, and B. Levine, “Autophagy modulation as a potential therapeutic target for diverse diseases,” Nature Reviews Drug Discovery, vol. 11, pp. 709–730, 2012. View at Google Scholar
  25. L. Galluzzi, J. M. Vicencio, O. Kepp, E. Tasdemir, M. C. Maiuri, and G. Kroemer, “To die or not to die: that is the autophagic question,” Current Molecular Medicine, vol. 8, no. 2, pp. 78–91, 2008. View at Publisher · View at Google Scholar · View at Scopus
  26. M. Sakai, H. Miyake, S. Tashiro, Y. Okumura, and H. Kido, “Inhibitory effect of FK506 and cyclosporine A on the growth and invasion of human liver cancer cells,” The Journal of Medical Investigation, vol. 51, no. 1-2, pp. 63–69, 2004. View at Publisher · View at Google Scholar · View at Scopus
  27. K. Migita and K. Eguchi, “FK 506-mediated T-cell apoptosis induction,” Transplantation Proceedings, vol. 33, no. 3, pp. 2292–2293, 2001. View at Google Scholar · View at Scopus
  28. P. Lu, Y. Nakamoto, Y. Nemoto-Sasaki et al., “Potential interaction between CCR1 and its ligand, CCL3, induced by endogenously produced interleukin-1 in human hepatomas,” American Journal of Pathology, vol. 162, no. 4, pp. 1249–1258, 2003. View at Google Scholar · View at Scopus
  29. J. Akiba, H. Yano, S. Ogasawara, K. Higaki, and M. Kojiro, “Expression and function of interleukin-8 in human hepatocellular carcinoma,” International Journal of Oncology, vol. 18, no. 2, pp. 257–264, 2001. View at Google Scholar · View at Scopus
  30. T. J. Standiford, R. M. Strieter, R. M. Allen, M. D. Burdick, and S. L. Kunkel, “IL-7 up-regulates the expression of IL-8 from resting and stimulated human blood monocytes,” Journal of Immunology, vol. 149, no. 6, pp. 2035–2039, 1992. View at Google Scholar · View at Scopus
  31. H. Ataseven, I. H. Bahcecioglu, N. Kuzu et al., “The levels of ghrelin, leptin, TNF-α, and IL-6 in liver cirrhosis and hepatocellular carcinoma due to HBV and HDV infection,” Mediators of Inflammation, vol. 2006, Article ID 78380, 6 pages, 2006. View at Publisher · View at Google Scholar · View at Scopus
  32. I. Fabregat, “Dysregulation of apoptosis in hepatocellular carcinoma cells,” World Journal of Gastroenterology, vol. 15, no. 5, pp. 513–520, 2009. View at Publisher · View at Google Scholar · View at Scopus
  33. X.-R. Xu, J. Huang, Z.-G. Xu et al., “Insight into hepatocellular carcinogenesis at transcriptome level by comparing gene expression profiles of hepatocellular carcinoma with those of corresponding noncancerous liver,” Proceedings of the National Academy of Sciences of the United States of America, vol. 98, no. 26, pp. 15089–15094, 2001. View at Publisher · View at Google Scholar · View at Scopus
  34. W.-Y. Wu, J. Li, Z.-S. Wu, C.-L. Zhang, and X.-L. Meng, “STAT3 activation in monocytes accelerates liver cancer progression,” BMC Cancer, vol. 11, article no. 506, 2011. View at Publisher · View at Google Scholar · View at Scopus
  35. J. Li, G. K.-K. Lau, L. Chen et al., “Interleukin 17a promotes hepatocellular carcinoma metastasis via NF-kB induced matrix metalloproteinases 2 and 9 expression,” PLoS ONE, vol. 6, no. 7, Article ID e21816, 2011. View at Publisher · View at Google Scholar · View at Scopus
  36. E. Carballo, W. S. Lai, and P. J. Blackshear, “Feedback inhibition of macrophage tumor necrosis factor-α production by tristetraprolin,” Science, vol. 281, no. 5379, pp. 1001–1005, 1998. View at Google Scholar · View at Scopus
  37. L. Williams, L. Bradley, A. Smith, and B. Foxwell, “Signal transducer and activator of transcription 3 is the dominant mediator of the anti-inflammatory effects of IL-10 in human macrophages,” Journal of Immunology, vol. 172, no. 1, pp. 567–576, 2004. View at Google Scholar · View at Scopus
  38. T. Copetti, C. Bertoli, E. Dalla, F. Demarchi, and C. Schneider, “p65/RelA modulates BECN1 transcription and autophagy,” Molecular and Cellular Biology, vol. 29, no. 10, pp. 2594–2608, 2009. View at Publisher · View at Google Scholar · View at Scopus
  39. J. X. Chen, X. D. Xu, W. H. Chen, and X. Z. Zhang, “Multi-functional envelope-type nanoparticles assembled from amphiphilic peptidic prodrug with improved anti-tumor activity,” ACS Applied Materials & Interfaces, vol. 6, no. 1, pp. 593–598, 2014. View at Google Scholar
  40. A. Mittal, S. Tabasum, and R. P. Singh, “Berberine in combination with doxorubicin suppresses growth of murine melanoma B16F10 cells in culture and xenograft,” Phytomedicine, 2013. View at Publisher · View at Google Scholar